Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
There is a ready market for blood tests that do not involve putting a needle to a vein. Can a new partnership meet the demand?
The deal between Sangamo and Biogen marks another endorsement of a gene-editing technology that many had written off years ago.
For diabetes devices interoperability is key, and partnerships between Insulet, Dexcom and Abbott show that rival groups see the benefits of working together.
Drug developers have directed almost half of their dealmaking firepower at oncology projects over the past five years, with cardiovascular a distant second.
Pfizer’s chief executive has pledged to throw money at the pharma giant’s thin pipeline and shirk financial engineering, but only canny deal-making will keep investors on…
Last year saw a dip in licensing deals across biopharma, though up-front payments held up and in some areas jumped considerably.
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.